Nuvation Bio (NUVB)

• Market cap: $1.54B
• 1 day: 1.6%
• 5 days: -0.67%
• 1 month: -23.05%
• 3 months: -47.83%
• 6 months: 40.95%
• Year to date: -48.25%
• 1 year: 100.9%
• 5 years: -68.4%
• 10 years: -54.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Employees: 298